Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: A multicenter experience

Alan T. Villavicencio, Sigita Burneikiene, Pantaleo Romanelli, Laura Fariselli, Lee McNeely, John D. Lipani, Steven D. Chang, E. Lee Nelson, Melinda McIntyre, Giovanni Broggi, John R. Adler

Research output: Contribution to journalArticle

Abstract

Despite decades of clinical trials investigating new treatment modalities for glioblastoma multiforme (GBM), there have been no significant treatment advances since the 1980s. Reported median survival times for patients with GBM treated with current modalities generally range from 9 to 19 months. The purpose of the current study is to retrospectively review the ability of CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA) radiosurgery to provide local tumor control of newly diagnosed or recurrent GBM. Twenty patients (43.5 %) underwent CyberKnife treatment at the time of the initial diagnosis and/or during the first 3 months of their initial clinical management. Twenty-six patients (56.5%) were treated at the time of tumor recurrence or progression. CyberKnife was performed in addition to the traditional therapy. The median survival from diagnosis for the patients treated with CyberKnife as an initial clinical therapy was 11.5 months (range, 2-33) compared to 21 months (range, 8-96) for the patients treated at the time of tumor recurrence/ progression. This difference was statistically significant (Kaplan-Meier analysis, P=0.0004). The median survival from the CyberKnife treatment was 9.5 months (range, 0.25-31 months) and 7 months (range, 1-34 months) for patients in the newly diagnosed and recurrent GBM groups (Kaplan-Meier analysis, P=0.79), respectively. Cox proportional hazards survival regression analysis demonstrated that survival time did not correlate significantly with treatment parameters (D max, D min, number of fractions) or target volume. Survival time and recursive partitioning analysis class were not correlated (P=0.07). Patients with more extensive surgical interventions survived longer (P=0.008), especially those who underwent total tumor resection vs. biopsy (P=0.004). There is no apparent survival advantage in using CyberKnife in initial management of glioblastoma patients, and it should be reserved for patients whose tumors recur or progress after conventional therapy.

Original languageEnglish
Pages (from-to)417-424
Number of pages8
JournalNeurosurgical Review
Volume32
Issue number4
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Radiosurgery
Glioblastoma
Survival
Kaplan-Meier Estimate
Therapeutics
Neoplasms
Recurrence
Survival Analysis
Regression Analysis
Clinical Trials
Biopsy

Keywords

  • Brain tumors
  • Cyberknife radiosurgery
  • Glioblastoma multiforme
  • Multicenter study
  • Stereotactic radiosurgery
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme : A multicenter experience. / Villavicencio, Alan T.; Burneikiene, Sigita; Romanelli, Pantaleo; Fariselli, Laura; McNeely, Lee; Lipani, John D.; Chang, Steven D.; Nelson, E. Lee; McIntyre, Melinda; Broggi, Giovanni; Adler, John R.

In: Neurosurgical Review, Vol. 32, No. 4, 10.2009, p. 417-424.

Research output: Contribution to journalArticle

Villavicencio, AT, Burneikiene, S, Romanelli, P, Fariselli, L, McNeely, L, Lipani, JD, Chang, SD, Nelson, EL, McIntyre, M, Broggi, G & Adler, JR 2009, 'Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: A multicenter experience', Neurosurgical Review, vol. 32, no. 4, pp. 417-424. https://doi.org/10.1007/s10143-009-0212-6
Villavicencio, Alan T. ; Burneikiene, Sigita ; Romanelli, Pantaleo ; Fariselli, Laura ; McNeely, Lee ; Lipani, John D. ; Chang, Steven D. ; Nelson, E. Lee ; McIntyre, Melinda ; Broggi, Giovanni ; Adler, John R. / Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme : A multicenter experience. In: Neurosurgical Review. 2009 ; Vol. 32, No. 4. pp. 417-424.
@article{0b13af9f07f14650b6c5d088c6904345,
title = "Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: A multicenter experience",
abstract = "Despite decades of clinical trials investigating new treatment modalities for glioblastoma multiforme (GBM), there have been no significant treatment advances since the 1980s. Reported median survival times for patients with GBM treated with current modalities generally range from 9 to 19 months. The purpose of the current study is to retrospectively review the ability of CyberKnife{\circledR} (Accuray Incorporated, Sunnyvale, CA, USA) radiosurgery to provide local tumor control of newly diagnosed or recurrent GBM. Twenty patients (43.5 {\%}) underwent CyberKnife treatment at the time of the initial diagnosis and/or during the first 3 months of their initial clinical management. Twenty-six patients (56.5{\%}) were treated at the time of tumor recurrence or progression. CyberKnife was performed in addition to the traditional therapy. The median survival from diagnosis for the patients treated with CyberKnife as an initial clinical therapy was 11.5 months (range, 2-33) compared to 21 months (range, 8-96) for the patients treated at the time of tumor recurrence/ progression. This difference was statistically significant (Kaplan-Meier analysis, P=0.0004). The median survival from the CyberKnife treatment was 9.5 months (range, 0.25-31 months) and 7 months (range, 1-34 months) for patients in the newly diagnosed and recurrent GBM groups (Kaplan-Meier analysis, P=0.79), respectively. Cox proportional hazards survival regression analysis demonstrated that survival time did not correlate significantly with treatment parameters (D max, D min, number of fractions) or target volume. Survival time and recursive partitioning analysis class were not correlated (P=0.07). Patients with more extensive surgical interventions survived longer (P=0.008), especially those who underwent total tumor resection vs. biopsy (P=0.004). There is no apparent survival advantage in using CyberKnife in initial management of glioblastoma patients, and it should be reserved for patients whose tumors recur or progress after conventional therapy.",
keywords = "Brain tumors, Cyberknife radiosurgery, Glioblastoma multiforme, Multicenter study, Stereotactic radiosurgery, Survival",
author = "Villavicencio, {Alan T.} and Sigita Burneikiene and Pantaleo Romanelli and Laura Fariselli and Lee McNeely and Lipani, {John D.} and Chang, {Steven D.} and Nelson, {E. Lee} and Melinda McIntyre and Giovanni Broggi and Adler, {John R.}",
year = "2009",
month = "10",
doi = "10.1007/s10143-009-0212-6",
language = "English",
volume = "32",
pages = "417--424",
journal = "Neurosurgical Review",
issn = "0344-5607",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme

T2 - A multicenter experience

AU - Villavicencio, Alan T.

AU - Burneikiene, Sigita

AU - Romanelli, Pantaleo

AU - Fariselli, Laura

AU - McNeely, Lee

AU - Lipani, John D.

AU - Chang, Steven D.

AU - Nelson, E. Lee

AU - McIntyre, Melinda

AU - Broggi, Giovanni

AU - Adler, John R.

PY - 2009/10

Y1 - 2009/10

N2 - Despite decades of clinical trials investigating new treatment modalities for glioblastoma multiforme (GBM), there have been no significant treatment advances since the 1980s. Reported median survival times for patients with GBM treated with current modalities generally range from 9 to 19 months. The purpose of the current study is to retrospectively review the ability of CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA) radiosurgery to provide local tumor control of newly diagnosed or recurrent GBM. Twenty patients (43.5 %) underwent CyberKnife treatment at the time of the initial diagnosis and/or during the first 3 months of their initial clinical management. Twenty-six patients (56.5%) were treated at the time of tumor recurrence or progression. CyberKnife was performed in addition to the traditional therapy. The median survival from diagnosis for the patients treated with CyberKnife as an initial clinical therapy was 11.5 months (range, 2-33) compared to 21 months (range, 8-96) for the patients treated at the time of tumor recurrence/ progression. This difference was statistically significant (Kaplan-Meier analysis, P=0.0004). The median survival from the CyberKnife treatment was 9.5 months (range, 0.25-31 months) and 7 months (range, 1-34 months) for patients in the newly diagnosed and recurrent GBM groups (Kaplan-Meier analysis, P=0.79), respectively. Cox proportional hazards survival regression analysis demonstrated that survival time did not correlate significantly with treatment parameters (D max, D min, number of fractions) or target volume. Survival time and recursive partitioning analysis class were not correlated (P=0.07). Patients with more extensive surgical interventions survived longer (P=0.008), especially those who underwent total tumor resection vs. biopsy (P=0.004). There is no apparent survival advantage in using CyberKnife in initial management of glioblastoma patients, and it should be reserved for patients whose tumors recur or progress after conventional therapy.

AB - Despite decades of clinical trials investigating new treatment modalities for glioblastoma multiforme (GBM), there have been no significant treatment advances since the 1980s. Reported median survival times for patients with GBM treated with current modalities generally range from 9 to 19 months. The purpose of the current study is to retrospectively review the ability of CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA) radiosurgery to provide local tumor control of newly diagnosed or recurrent GBM. Twenty patients (43.5 %) underwent CyberKnife treatment at the time of the initial diagnosis and/or during the first 3 months of their initial clinical management. Twenty-six patients (56.5%) were treated at the time of tumor recurrence or progression. CyberKnife was performed in addition to the traditional therapy. The median survival from diagnosis for the patients treated with CyberKnife as an initial clinical therapy was 11.5 months (range, 2-33) compared to 21 months (range, 8-96) for the patients treated at the time of tumor recurrence/ progression. This difference was statistically significant (Kaplan-Meier analysis, P=0.0004). The median survival from the CyberKnife treatment was 9.5 months (range, 0.25-31 months) and 7 months (range, 1-34 months) for patients in the newly diagnosed and recurrent GBM groups (Kaplan-Meier analysis, P=0.79), respectively. Cox proportional hazards survival regression analysis demonstrated that survival time did not correlate significantly with treatment parameters (D max, D min, number of fractions) or target volume. Survival time and recursive partitioning analysis class were not correlated (P=0.07). Patients with more extensive surgical interventions survived longer (P=0.008), especially those who underwent total tumor resection vs. biopsy (P=0.004). There is no apparent survival advantage in using CyberKnife in initial management of glioblastoma patients, and it should be reserved for patients whose tumors recur or progress after conventional therapy.

KW - Brain tumors

KW - Cyberknife radiosurgery

KW - Glioblastoma multiforme

KW - Multicenter study

KW - Stereotactic radiosurgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=69949136127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949136127&partnerID=8YFLogxK

U2 - 10.1007/s10143-009-0212-6

DO - 10.1007/s10143-009-0212-6

M3 - Article

C2 - 19633875

AN - SCOPUS:69949136127

VL - 32

SP - 417

EP - 424

JO - Neurosurgical Review

JF - Neurosurgical Review

SN - 0344-5607

IS - 4

ER -